<a href="https://www.medchemexpress.com/Silodosin.html">Silodosin</a>產品描述:Silodosin (Rapaflo; KMD-3213) is an α1-adrenoceptor antagonist with high uroselectivity; In treatment of dysuria. IC50 Value: Target: Adrenergic Receptor in vitro: Silodosin potently inhibited 2-[2-(4-hydroxy-3-[125I]iodophenyl)ethylaminomethyl]-alpha-tetralone binding to the cloned human alpha 1a-AR, with a Ki value of 0.036 nM, but had 583- and 56-fold lower potency at the alpha 1b- and alpha 1d-ARs, respectively. Silodosin inhibited norepinephrine-induced increases in intracellular Ca2+ concentrations in alpha 1a-AR-expressing Chinese hamster ovary cells with an IC50 of 0.32 nM but had a much weaker inhibitory effect on the alpha 1b- and alpha 1d-ARs. in vivo: Using pharmacologically well characterized native rat tissues [submaxillary gland (alpha 1A-AR-expressing tissue), liver (alpha 1B-AR-expressing tissue), and heart (mixed alpha 1A- and alpha 1B-AR-expressing tissue)], binding studies showed that inhibition curves for Silodosin in submaxillary gland and liver best fit a on<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網點遍及全球20多個國家地區(qū)。MCE經過多年努力已成為全球生物活性小分子領域的一流供應商, 產品涵蓋癌癥、神經科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產品都進行嚴格的LCMS和NMR檢驗,其產品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數千種產品在上海有充足備貨,24-48小時內送達客戶;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產品提供免費試用裝;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。</span><br><br>產品鏈接:<a href="http://www.medchemexpress.cn/silodosin.html">www.medchemexpress.cn/silodosin.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
Silodosin研究進展
發(fā)布日期:2017-10-27 瀏覽次數:0
核心提示:a href=https://www.medchemexpress.com/Silodosin.htmlSilodosin/a產品描述:Silodosin (Rapaflo; KMD-3213) is an 1-adrenocep
- 下一篇:暫無
- 上一篇:Org-26576研究進展
行業(yè)動態(tài)
更多...
- Silodosin研究進展 10-27
- Org-26576研究進展 10-27
- Evobrutinib研究進展 10-27
- UK-371804研究進展 10-27
- Asenapine研究進展 10-27
- GJ103 (sodium salt)研究 10-27
- GSK682753A研究進展 10-27
- Monastrol研究進展 10-27
- SMCC-DM1研究進展 10-27
- TOFA研究進展 10-27